A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression

ID Number 16-1422

Principal Investigator(s)
Joshua Brody

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called nivolumab in combination with brentuximab vedotin.  Nivolumab is an antibody that is being tested to see if it will allow the body's immune system to work against tumor cells.  Brentuximab vedotin is an antibody-drug conjugate.  The antibody part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.

Contact Information
Dana Ostrowski
(212) 824-7309

Recruiting Patients: Yes